2019
Comparison of Survival Rates After a Combination of Local Treatment and Systemic Therapy vs Systemic Therapy Alone for Treatment of Stage IV Non–Small Cell Lung Cancer
Uhlig J, Case MD, Blasberg JD, Boffa DJ, Chiang A, Gettinger SN, Kim HS. Comparison of Survival Rates After a Combination of Local Treatment and Systemic Therapy vs Systemic Therapy Alone for Treatment of Stage IV Non–Small Cell Lung Cancer. JAMA Network Open 2019, 2: e199702. PMID: 31433481, PMCID: PMC6707019, DOI: 10.1001/jamanetworkopen.2019.9702.Peer-Reviewed Original ResearchMeSH KeywordsAblation TechniquesAdolescentAdultAgedAged, 80 and overAntineoplastic AgentsCarcinoma, Non-Small-Cell LungChemotherapy, AdjuvantComparative Effectiveness ResearchDatabases, FactualFemaleFollow-Up StudiesHumansLung NeoplasmsMaleMiddle AgedNeoplasm MetastasisNeoplasm StagingPneumonectomyProportional Hazards ModelsRadiotherapy, AdjuvantRetrospective StudiesSurvival RateTreatment OutcomeYoung AdultConceptsStage IV non-small cell lung cancerNon-small cell lung cancerPrimary tumor siteSuperior overall survivalSystemic therapySurgical resectionCell lung cancerExternal beam radiotherapyOverall survivalSurvival benefitLocal treatmentTumor siteTumor characteristicsLung cancerTreatment groupsMultivariable Cox proportional hazards regression modelsOligometastatic non-small cell lung cancerStage IV squamous cell carcinomaSurvival rateCox proportional hazards regression modelProportional hazards regression modelsComparative effectiveness research studyCancer-specific factorsNational Cancer DatabaseStage IV disease
2018
Survival Rates after Thermal Ablation versus Stereotactic Radiation Therapy for Stage 1 Non-Small Cell Lung Cancer: A National Cancer Database Study.
Uhlig J, Ludwig JM, Goldberg SB, Chiang A, Blasberg JD, Kim HS. Survival Rates after Thermal Ablation versus Stereotactic Radiation Therapy for Stage 1 Non-Small Cell Lung Cancer: A National Cancer Database Study. Radiology 2018, 289: 862-870. PMID: 30226453, DOI: 10.1148/radiol.2018180979.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerStage 1 non-small cell lung cancerStereotactic radiation therapyCell lung cancerOverall survivalLung cancerThermal ablationRadiation therapySurvival ratePropensity score-matched cohortUnplanned hospital readmission ratesNational Cancer DatabaseUnplanned hospital readmissionOverall survival rateHospital readmission ratesSmaller tumor sizeMore comorbiditiesReadmission ratesHospital readmissionRetrospective studyTumor sizePotential confoundersCancer DatabasePrimary treatmentPatients
2016
Timing of Surgery after Neoadjuvant Chemoradiation in Locally Advanced Non–Small Cell Lung Cancer
Gao SJ, Corso CD, Wang EH, Blasberg JD, Detterbeck FC, Boffa DJ, Decker RH, Kim AW. Timing of Surgery after Neoadjuvant Chemoradiation in Locally Advanced Non–Small Cell Lung Cancer. Journal Of Thoracic Oncology 2016, 12: 314-322. PMID: 27720827, DOI: 10.1016/j.jtho.2016.09.122.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaCarcinoma, Large CellCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellChemoradiotherapy, AdjuvantCombined Modality TherapyFemaleFollow-Up StudiesHumansLung NeoplasmsMaleMiddle AgedNeoadjuvant TherapyNeoplasm StagingPneumonectomyPrognosisRetrospective StudiesSurvival RateTime FactorsConceptsNational Cancer Data BaseNeoadjuvant chemoradiationTiming of surgeryOverall survivalAdvanced non-small cell lung cancerNon-small cell lung cancerStage IIIA-N2 NSCLCStage IIIA NSCLCKaplan-Meier methodOverall survival rateSubset of patientsCell lung cancerLog-rank testMultivariate survival analysisProportional hazards modelIIIA NSCLCN2 NSCLCNeoadjuvant therapyTrimodality therapySurgical resectionClinical stageRetrospective studyLung cancerHazards modelSurvival rateResection is safe for patients with stage IIIA NSCLC undergoing multimodality therapy
Lushaj E, Julliard W, Bretl T, Badami A, Macke R, Blasberg J, Maloney J. Resection is safe for patients with stage IIIA NSCLC undergoing multimodality therapy. Cancer Treatment And Research Communications 2016, 5: 22-25. DOI: 10.1016/j.ctrc.2015.12.002.Peer-Reviewed Original ResearchNon-small cell lung cancerIIIA non-small cell lung cancerStage IIIA non-small cell lung cancerStage I non-small cell lung cancerVideo-assisted thoracoscopic surgeryStage IIIA patientsIIIA patientsStage IStage IIMultimodality therapySurvival rateMedian hospital lengthOverall survival rateResults Mean ageCell lung cancerPost-treatment survivalInitial therapyAdvanced diseaseHospital lengthNeoadjuvant radiationPerioperative morbidityPulmonary resectionThoracoscopic surgeryOptimal therapySurgical intervention